Key Points Interested in Agenus Inc.? Here are five stocks we like better. Agenus is prioritizing its Phase 3 ROBBIN trial of ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...
For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase ...
The researchers found that the benefit from neoadjuvant therapy was consistent across a range of factors including patient age, sex, performance status, and stage of disease. They also found that the ...
The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 ...
Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma. Treatment with neoadjuvant and ...
A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results